Thyroid

ENDO 2024: Teprotumumab leads to sustained relief from thyroid eye disease symptoms

June 10, 2024

Among the 112 patients who received 7-8 infusions of teprotumumab for thyroid eye disease (TED) in the OPTIC and OPTIC-X studies, the long-term response as observed 51 weeks after therapy was similar to week 24 results in the controlled clinical trials. Inflammatory and ophthalmic composite outcome improvements were seen in 90% of patients with nearly 70% reporting improvement in diplopia and proptosis. Further, 82% of patients in this analysis didn't report additional TED treatment (including surgery) over 99 weeks following the final teprotumumab dose.

• Responses, including clinical activity score (CAS ≥2-point improvement), the European Group of Graves' Orbitopathy ophthalmic composite outcome, diplopia (≥1 Gorman grade improvement), proptosis (≥2 mm improvement), overall (improvement in proptosis + CAS), and disease inactivation (CAS ≤1), were assessed and pooled from study baseline to week 24 (formal study) and up to week 72 (formal follow-up). Graves' ophthalmopathy quality-of-life (GO-QoL) scores were also assessed.
• At week 72 follow-up, 91.2%, 89.5%, 72.9%, 67.9%, and 66.1% of patients were responders for CAS, composite outcome, diplopia, proptosis, and overall response, respectively.
• The mean reduction in proptosis was 2.68 mm, mean GO-QoL improvement was 15.22, and disease inactivation was detected in 70.2%.

Source:

Kahaly GJ, et al. (2024, June 2). Thyroid. Long-Term Efficacy of Teprotumumab in Thyroid Eye Disease: Follow-Up Outcomes in Three Clinical Trials. https://pubmed.ncbi.nlm.nih.gov/38824618/